InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
58,657.19
(
1.32%
)
Post# of 39884
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

sharonc

Send PM Follow Ignore
Followers 0
Posts 66
Boards Moderated 0
Alias Born 03/27/2013

sharonc

Re: DollarsOnPennies post# 35100

Friday, 03/23/2018 7:19:14 AM

Friday, March 23, 2018 7:19:14 AM

Post# of 39884
APD371, an agonist of the cannabinoid receptor 2, is actually in a small Phase 2, 8-week trial for visceral pain associated with Ulcerative Colitis. The company was very pleased with how well the single and multiple dose phase 1 trials went. The company was able to test higher doses of the drug than they thought possible without side effect issues.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up